ATI-2341

Name	ATI-2341
Synonyms	ATI2341 ATI 2341 ATI-2341 PALM-MET-GLY-TYR-GLN-LYS-LYS-LEU-ARG-SER-MET-THR-ASP-LYS-TYR-ARG-LEU-OH L-Leucine, N-(1-oxohexadecyl)-L-methionylglycyl-L-tyrosyl-L-glutaminyl-L-lysyl-L-lysyl-L-leucyl-L-arginyl-L-seryl-L-methionyl-L-threonyl-L-α-aspartyl-L-lysyl-L-tyrosyl-L-arginyl-
CAS	1337878-62-2

Molecular Formula	C104H178N26O25S2
Molar Mass	2256.85
Density	1.36±0.1 g/cm3(Predicted)
Storage Condition	-20℃
In vitro study	ATI-2341 induces CXCR4-and G-protein dependent signaling pathways, in vivo migration, and chemotaxis in CXCR4 expressing cells. It is a potent agonist with an EC50 of 194±16 nM and an intrinsic activity of 81±4%. ATI-2341 is a potent mobilizer of bone marrow polymorphonuclear neutrophils and hematopoietic stem/progenitor cells and may be a therapeutic approach for the recruitment of hematopoietic stem/progenitor cells prior to autologous bone marrow transplantation. ATI-2341 can induce chemotaxis in CCRF-CEM cells.
In vivo study	Intraperitoneal injection of ATI-2341 in BALB/c mice will cause recruitment of polymorphonuclear neutrophils to the peritoneum to the peritoneum, with maximal effect at an injection concentration of 450nmol/kg. Higher concentrations will reduce the effect on cell recruitment. Intravenous injection of ATI-2341 into mice will cause a dose-dependent increase in polymorphonuclear neutrophils in the peripheral circulation. The maximum effect was achieved at an injection concentration of 0.66 μmol/kg. Of the concentrations tested, ATI-2341 had no effect on lymphocyte mobilization.

biological activity	ATI-2341, a peptide targeting C- X-C type 4 chemokine receptor (CXCR4), is an allosteric receptor agonist, which can activate heterotrimeric G protein (Gi), inhibit cAMP production and induce calcium mobilization.
target	TargetValue CXCR4 (in CCRF-CEM cells) 194 nM(EC50)
Target	Value
CXCR4 (in CCRF-CEM cells)	194 nM(EC50)
in vitro study	ATI-2341 induce CXCR4-and G protein-dependent signaling pathways, receptor in vivo migration and chemotaxis in CXCR4-expressing cells. It is an effective agonist with EC50 as 194±16 nM and intrinsic activity as 81±4%. ATI-2341 is an effective mobilizer for bone marrow polymorphonuclear neutrophils and hematopoietic stem progenitor cells, and may serve as a treatment for recruiting hematopoietic stem progenitor cells prior to autologous bone marrow transplantation. ATI-2341 can induce chemotaxis in CCRF-CEM cells.
in vivo study	intraperitoneal injection of ATI-2341 into BALB/c mice will cause polymorphonuclear neutrophils to be recruited to the peritoneum, reaching the maximum effect when the injection concentration is 450nmol/kg. Higher concentrations will reduce the recruitment effect on cells. Intravenous injection of ATI-2341 into mice will cause a dose-dependent increase in polymorphonuclear neutrophils in the peripheral circulation. The maximum effect was achieved at an injection concentration of 0.66 μmol/kg. In the concentrations detected, ATI-2341 had no effect on lymphocyte mobilization.

Last Update：2024-04-09 21:04:16

Product Name: ATI-2341 Visit Supplier Webpage Request for quotation
CAS: 1337878-62-2
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409

Wechat: 18301782025

Product Name: ATI-2341 Visit Supplier Webpage Request for quotation
CAS: 1337878-62-2
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409

Wechat: 18301782025

View History

ATI-2341

ATI-2341 Request for Quotation